CD34 and acute myeloid leukemia: We have previously shown that a small subset of primary AML samples are sensitive to the MCL1 inhibitor S63845 in long-term clonogenic assays, with less toxicity observed in normal donor CD34 + cells, highlighting a therapeutic window for MCL1 targeting leukemic progenitors [8].